30 completed, 10 terminated, 1 withdrawn. 15 Phase 2, 10 Phase 3, 7 Phase 4, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 10, Terminated 5 |
| Phase 3 | 10 | Completed 9, Terminated 1 |
| Phase 4 | 7 | Completed 4, Terminated 2, Withdrawn 1 |
| Phase 1 | 5 | Terminated 3, Completed 2 |
Follow Elan Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia ELND005, Placebo - Down Syndrome | Phase 2 | Completed | OPKO Health, Inc. | 23 | 2013-09-01 | 2019-11-04 |
| A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease Group 1 ELND005, Group 2 ELND005 - Alzheimer's Disease | Phase 2 | Terminated | OPKO Health, Inc. | 296 | 2013-01-01 | 2019-10-21 |
| Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease ELND005, Placebo - Alzheimer's Disease | Phase 2 | Completed | OPKO Health, Inc. | 350 | 2012-11-01 | 2019-10-21 |
| Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder ELND005, Lamotrigine, Valproic acid - Bipolar 1 Disorder | Phase 2 | Terminated | OPKO Health, Inc. | 309 | 2012-08-01 | 2019-10-21 |
| Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control Multiple Sclerosis | Completed | John F. Foley, MD | 164 | 2012-07-01 | 2013-06-14 | |
| A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis ELND002 - Multiple Sclerosis | Phase 1 | Terminated | Elan Pharmaceuticals | 12 | 2010-12-01 | 2015-12-14 |
| Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) Methylprednisolone, Prednisolone - Immune Reconstitution Inflammatory Syndrome, Leukoencephalopathy, Progressive Multifocal | Phase 4 | Terminated | Biogen | 3 | 2010-09-01 | 2014-09-05 |
| Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis BG00002 (natalizumab), interferon beta-1a, glatiramer acetate - Relapsing Remitting Multiple Sclerosis | Phase 3 | Terminated | Biogen | 84 | 2010-03-01 | 2014-09-03 |
| Treatment Interruption of Natalizumab natalizumab, interferon beta 1-a, methylprednisolone - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Biogen | 175 | 2010-03-01 | 2013-09-19 |
| A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis ELND002, Placebo - Multiple Sclerosis | Phase 1 | Terminated | Elan Pharmaceuticals | 32 | 2010-03-01 | 2015-12-14 |
| JC-Virus (JCV) Antibody Program Tysabri® (natalizumab) - Multiple Sclerosis | Completed | Biogen | 1096 | 2010-03-01 | 2016-10-05 | |
| A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients BG00002 (natalizumab) - Relapsing Remitting Multiple Sclerosis (RRMS) | Phase 4 | Completed | Biogen | 224 | 2009-08-01 | 2017-03-21 |
| Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) mefloquine - Progressive Multifocal Leukoencephalopathy | Phase 1 / Phase 2 | Terminated | Biogen | 37 | 2009-01-01 | 2014-07-31 |
| Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy natalizumab - Crohn's Disease | Phase 4 | Withdrawn | Biogen | 2008-12-01 | 2016-06-16 | |
| A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State Natalizumab - Multiple Sclerosis | Phase 4 | Completed | Biogen | 20 | 2008-11-01 | 2015-02-10 |
| ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay. Multiple Sclerosis | Completed | Biogen | 100 | 2008-03-01 | 2010-03-05 | |
| Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) natalizumab, standard of care - Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | Phase 1 | Completed | Biogen | 76 | 2007-10-01 | 2014-09-09 |
| Evaluation of Natalizumab for thE Relief of MS Associated FatiGue Multiple Sclerosis | Completed | Biogen | 89 | 2007-08-01 | 2023-08-22 | |
| Pregnancy Exposure Registry for Tysabri® Crohn's Disease, Prenatal Exposure | Completed | Biogen | 376 | 2007-01-01 | 2014-08-11 | |
| Natalizumab High Titer Immunogenicity and Safety BG00002-E (natalizumab high titer) - Multiple Sclerosis | Phase 2 | Completed | Biogen | 113 | 2006-10-01 | 2014-05-15 |
Showing 20 of 41. Sign in to see all of them.
Multiple Sclerosis (14) · Multiple Sclerosis, Relapsing-Remitting (9) · Crohn Disease (8) · Aggression (2) · Alzheimer Disease (2) · Arthritis, Rheumatoid (2) · Leukoencephalopathy, Progressive Multifocal (2) · Pain (2) · Pneumonia (2) · Psychomotor Agitation (2) · Bacteremia (1) · Bipolar Disorder (1) · Central Nervous System Diseases (1) · Cerebral Palsy (1) · Colitis (1)
Natalizumab (20) · scyllitol (3) · Glatiramer Acetate (2) · Interferon beta-1a (2) · Methylprednisolone (2) · Zonisamide (2) · ziconotide (2) · Cefepime (1) · Ceftriaxone (1) · Lamotrigine (1) · Mefloquine (1) · Methylprednisolone Hemisuccinate (1) · Prednisolone (1) · Standard of Care (1) · Valproic Acid (1)
United States (34) · Canada (9) · Spain (6) · Germany (5) · France (4) · United Kingdom (4) · Belgium (3) · Czechia (3) · Italy (3) · Poland (3) · Romania (2) · Australia (1) · Austria (1) · Brazil (1) · Bulgaria (1)
Michael Panzara, MD, MPH (2) · Chris Polman, MD (1) · David L Paterson, MD (1) · John F Foley, MD (1) · Joseph A Paladino, PharmD (1) · Richard A Rudick, MD (1) · Samia J Khoury, MD (1) · Terence Sanger, MD, PhD (1)
PMID 16267322, PMID 37173129, PMID 16510744, PMID 16510745, PMID 22521274, PMID 23733308, PMID 26049148, PMID 27552976, PMID 28453471, PMID 38469809, PMID 38648580